TENX
NASDAQTenax Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks36-17%
2025-10-262026-04-19
Mix1490d
- SEC Filings7(50%)
- Other4(29%)
- Insider1(7%)
- Analyst1(7%)
- Leadership1(7%)
Latest news
25 items- SECSEC Form DEFA14A filed by Tenax Therapeutics Inc.DEFA14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form DEF 14A filed by Tenax Therapeutics Inc.DEF 14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form 8-K filed by Tenax Therapeutics Inc.8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerMr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience across management and corporate finance roles in the healthcare industry. He will replace Thomas McGauley, who has served as interim CFO since December 2024. "Tom br
- SECSEC Form EFFECT filed by Tenax Therapeutics Inc.EFFECT - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form S-3 filed by Tenax Therapeutics Inc.S-3 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- ANALYSTCantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price targetCantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00
- SECSEC Form 10-K filed by Tenax Therapeutics Inc.10-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECTenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateAchieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress. "We are pleased to announce that we have recently achieved our randomization target
- PRTenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceCHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL. Details of presentation:Format: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer; Stuart Rich, M.D., Chief Medical Officer; Douglas Randall, Chief Business OfficerDate and Time: March 10, 2026, at 2:20 p.m. ET The
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
- PRTenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY. Details of presentation:Format: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer; Douglas Randall, Chief Business OfficerDate and Time: February 11, 2026, at 12:30 p.m. ET The live and archived webcast of the p
- INSIDERSEC Form 4 filed by Interim CFO Mcgauley Thomas4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERSEC Form 4 filed by Director Davidson Michael H.4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERSEC Form 4 filed by CEO Giordano Christopher Thomas4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Rich Stuart4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERSEC Form 4 filed by Director Proehl Gerald T4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERSEC Form 4 filed by Director Almenoff June Sherie4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERSEC Form 4 filed by Director Doogan Declan4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERSEC Form 4 filed by Director Hunter Robyn4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- SECTenax Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECTenax Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Announces Result of Prespecifed Blinded Sample Size AssessmentPlanned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL demonstrated the trial is powered at well
- INSIDERChief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)